>
12 Glaring Realities Of Marxist Socialism
The EU & The Iron Law Of Oligarchy
Iron Ore Below $100 As UBS Warns "Fundamentals Are Deteriorating"
Global Bond Market On Edge As Japanese Yields Soar After "Horrible" 10Y JGB Auction
Voyager 1 approaches one light day from Earth
Renewable Energy Breakthrough! World's Most Efficient Tesla Turbine System
Meet Sunbird, a nuclear fusion-powered space tug concept from Pulsar Fusion.
China and Russia launch 29-nation AI alliance to rival western control of technology
BREAKING: China has begun manufacturing domestically developed Immersion Deep...
Idaho's High Desert Becomes Hot Spot For Nuclear Power Revolution
The World's Largest Electric Aircraft Is About to Take Its First Flight
Tesla Cybercabs and Superchargers Will Act as Mini Cell Towers for SpaceX Starlink

Like the horse of Troy, scientists at the Technion have developed a way to sneak synthetic cells right into tumor tissue, where they then begin producing cancer-fighting proteins from the inside. The technique was tested in both cell cultures and in mice, and found to be an effective treatment in both cases.
Cancer cells thrive thanks to some robust defense mechanisms, so finding ways to get past them is a key area of research. In the past, scientists have sent gold nanoparticles inside tumors by hitchhiking on white blood cells, before heating the gold with near-infrared light to kill the cancer from within. Others examined the possibility of administering a "prodrug" that remained inactive until it detected cancer markers, and then began producing drugs from inside the tumor.
The new work follows a similar function as the latter. The Technion scientists loaded molecular machines inside lipid-based particles that resemble biological cell membranes, creating what they call "nano-factories." Once they're activated by sensing the presence of abnormal cells, these particles kick into gear, producing specific therapeutic proteins and pulling the energy and building blocks they need from the tumor tissue around them.
"By coding the integrated DNA template, the particles we developed can produce a variety of protein medicines," says Avi Schroeder, one of the lead researchers on the study. "They are modular, meaning they allow for activation of protein production in accordance with the environmental conditions. Therefore, the artificial cells we've developed at the Technion may take an important part in the personalized medicine trend – adjustment of treatment to the genetic and medical profile of a specific patient."